我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。
相关临床试验
16
4 进行中
药物批准
3
批准总数
监管机构
1
监管机构数
成立时间
1996
进行中（未招募）
4
25.0%
已完成
10
62.5%
终止
6.3%
撤回
FDA
Food and Drug Administration
- Paratek's omadacycline demonstrated significant bacterial burden reduction in a Phase II trial for nontuberculous mycobacterial pulmonary disease caused by Mycobacterium abscessus complex. - The study showed 76.5% of omadacycline-treated patients experienced decreased culture scores compared to 45.8% of placebo patients, with 53.8% achieving negative cultures at day 84. - Omadacycline addresses a critical unmet need in NTM treatment, where nearly all current therapies are used off-label, and has received FDA fast-track and orphan drug designations.
